Tranzyme (TZYM) -66% premarket after reporting negative preliminary results from the first of...

|By:, SA News Editor

Tranzyme (TZYM) -66% premarket after reporting negative preliminary results from the first of two trials assessing its TZP-102 treatment for diabetic patients with a common stomach complication. Neither the 10mg dose group nor the 20mg dose group of TZP-102 patients reached statistical significance vs. a placebo.